PMID- 25949875
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 4
IP  - 2
DP  - 2015 Feb
TI  - Phase I trial of adoptively transferred tumor-infiltrating lymphocyte 
      immunotherapy following concurrent chemoradiotherapy in patients with 
      locoregionally advanced nasopharyngeal carcinoma.
PG  - e976507
LID - e976507
AB  - Adoptive cell therapy (ACT) for cancers using autologous tumor-infiltrating 
      lymphocytes (TILs) can induce immune responses and antitumor activity in 
      metastatic melanoma patients. Here, we aimed to assess the safety and antitumor 
      activity of ACT using expanded TILs following concurrent chemoradiotherapy (CCRT) 
      in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). 
      Twenty-three newly diagnosed, locoregionally advanced NPC patients were enrolled, 
      of whom 20 received a single-dose of TIL infusion following CCRT. All treated 
      patients were assessed for toxicity, survival and clinical and immunologic 
      responses. Correlations between immunological responses and treatment 
      effectiveness were further studied. Only mild adverse events (AEs), including 
      Grade 3 neutropenia (1/23, 5%) consistent with immune-related causes, were 
      observed. Nineteen of 20 patients exhibited an objective antitumor response, and 
      18 patients displayed disease-free survival longer than 12 mo after ACT. A 
      measurable plasma Epstein-Barr virus (EBV) load was detected in 14 patients at 
      diagnosis, but a measurable EBV load was not found in patients after one week of 
      ACT, and the plasma EBV load remained undetectable in 17 patients at 6 mo after 
      ACT. Expansion and persistence of T cells specific for EBV antigens in peripheral 
      blood following TIL therapy were observed in 13 patients. The apparent positive 
      correlation between tumor regression and the expansion of T cells specific for 
      EBV was further investigated in four patients. This study shows that NPC patients 
      can tolerate ACT with TILs following CCRT and that this treatment results in 
      sustained antitumor activity and anti-EBV immune responses. A larger phase II 
      trial is in progress.
FAU - Li, Jiang
AU  - Li J
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Biotherapy; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Chen, Qiu-Yan
AU  - Chen QY
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Nasopharyngeal Carcinoma ;
FAU - He, Jia
AU  - He J
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Biotherapy; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Li, Ze-Lei
AU  - Li ZL
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Biotherapy; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Tang, Xiao-Feng
AU  - Tang XF
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Biotherapy; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Chen, Shi-Ping
AU  - Chen SP
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Biotherapy; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Xie, Chuan-Miao
AU  - Xie CM
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Imaging Diagnostic and 
      Interventional Center; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Li, Yong-Qiang
AU  - Li YQ
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Biotherapy; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Huang, Li-Xi
AU  - Huang LX
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Biotherapy; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Ye, Shu-Bio
AU  - Ye SB
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Biotherapy; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Ke, Miao-La
AU  - Ke M
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Biotherapy; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Tang, Lin-Quan
AU  - Tang LQ
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Nasopharyngeal Carcinoma ;
FAU - Liu, Huai
AU  - Liu H
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Nasopharyngeal Carcinoma ;
FAU - Zhang, Lu
AU  - Zhang L
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Nasopharyngeal Carcinoma ;
FAU - Guo, Shan-Shan
AU  - Guo SS
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Nasopharyngeal Carcinoma ;
FAU - Xia, Jian-Chuan
AU  - Xia JC
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Biotherapy; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Zhang, Xiao-Shi
AU  - Zhang XS
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Biotherapy; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Zheng, Li-Min
AU  - Zheng LM
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Biotherapy; Sun Yat-sen University Cancer Center ; Guangzhou, China.
FAU - Guo, Xiang
AU  - Guo X
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Nasopharyngeal Carcinoma ;
FAU - Qian, Chao-Nan
AU  - Qian CN
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Nasopharyngeal Carcinoma ;
FAU - Mai, Hai-Qiang
AU  - Mai HQ
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China ; Department of 
      Nasopharyngeal Carcinoma ;
FAU - Zeng, Yi-Xin
AU  - Zeng YX
AD  - State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer 
      Center ; Guangzhou, China ; Collaborative Innovation Center of Cancer Medicine; 
      Sun Yat-sen University Cancer Center ; Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150306
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC4404907
OTO - NOTNLM
OT  - ACT, adoptive cell therapy
OT  - CCRT, concurrent chemoradiotherapy
OT  - CR, complete response
OT  - DFS, disease-free survival, EBNA1
OT  - EBV, Epstein-Barr virus
OT  - EBV-CTLs, EBV-specific cytotoxic T cells
OT  - ELISPOT, enzyme-linked immunospot
OT  - Epstein-Barr virus nuclear antigen 1
OT  - FACS, fluorescence-activated cell sorting
OT  - GMP, good manufacturing practices
OT  - LMP1, latent membrane protein-1
OT  - LMP2, latent membrane protein-2
OT  - NPC, nasopharyngeal carcinoma
OT  - PBMCs, peripheral blood mononuclear cells
OT  - PD, progressive disease
OT  - PR, partial response
OT  - REP, rapid expansion protocol
OT  - SFCs, spot-forming cells
OT  - TILs, tumor-infiltrating lymphocytes
OT  - adoptive cell therapy
OT  - nasopharyngeal carcinoma
OT  - tumor-infiltrating lymphocytes
EDAT- 2015/05/08 06:00
MHDA- 2015/05/08 06:01
PMCR- 2016/03/06
CRDT- 2015/05/08 06:00
PHST- 2014/08/07 00:00 [received]
PHST- 2014/10/10 00:00 [accepted]
PHST- 2015/05/08 06:00 [entrez]
PHST- 2015/05/08 06:00 [pubmed]
PHST- 2015/05/08 06:01 [medline]
PHST- 2016/03/06 00:00 [pmc-release]
AID - 976507 [pii]
AID - 10.4161/23723556.2014.976507 [doi]
PST - epublish
SO  - Oncoimmunology. 2015 Mar 6;4(2):e976507. doi: 10.4161/23723556.2014.976507. 
      eCollection 2015 Feb.